Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hesham Elhalawani

Showing results (11-20 of 86) with videos related to

Pageof 9
Sort By:
Future Oncology (London, England)|January 19, 2016
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Mona Fouad
Immunotherapy|October 30, 2015
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Mona Fouad
The Cochrane Database of Systematic Reviews|April 7, 2018
Gemcitabine-based chemotherapy for advanced biliary tract carcinomasOmar Abdel-Rahman, Zeinab Elsayed, Hesham Elhalawani
Future Oncology (London, England)|November 13, 2015
Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Hoda Ahmed
Expert Review of Respiratory Medicine|November 13, 2015
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysisOmar Abdel-Rahman, Hoda Ahmed, Hesham ElHalawani
Journal of Global Oncology|August 15, 2017
Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-AnalysisOmar Abdel-Rahman, Hesham ElHalawani, Hoda Ahmed
Expert Opinion on Drug Safety|September 24, 2015
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Mona Fouad
Future Oncology (London, England)|August 15, 2015
Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Mona Fouad
Future Oncology (London, England)|June 16, 2016
Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysisOmar Abdel-Rahman, Nermean Bahie Eldin, Hesham ElHalawani
Expert Opinion on Drug Safety|October 30, 2015
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidinesOmar Abdel-Rahman, Hesham ElHalawani, Shaimaa Essam-Eldin
Pageof 9

Showing results (11-20 of 86) with videos related to

Sort By:
Pageof 9
Future Oncology (London, England)|January 19, 2016
Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Mona Fouad
Immunotherapy|October 30, 2015
Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Mona Fouad
The Cochrane Database of Systematic Reviews|April 7, 2018
Gemcitabine-based chemotherapy for advanced biliary tract carcinomasOmar Abdel-Rahman, Zeinab Elsayed, Hesham Elhalawani
Future Oncology (London, England)|November 13, 2015
Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Hoda Ahmed
Expert Review of Respiratory Medicine|November 13, 2015
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysisOmar Abdel-Rahman, Hoda Ahmed, Hesham ElHalawani
Journal of Global Oncology|August 15, 2017
Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-AnalysisOmar Abdel-Rahman, Hesham ElHalawani, Hoda Ahmed
Expert Opinion on Drug Safety|September 24, 2015
Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Mona Fouad
Future Oncology (London, England)|August 15, 2015
Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysisOmar Abdel-Rahman, Hesham ElHalawani, Mona Fouad
Future Oncology (London, England)|June 16, 2016
Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysisOmar Abdel-Rahman, Nermean Bahie Eldin, Hesham ElHalawani
Expert Opinion on Drug Safety|October 30, 2015
S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidinesOmar Abdel-Rahman, Hesham ElHalawani, Shaimaa Essam-Eldin
Pageof 9